TScan Therapeutics, Inc.
TCRX
$1.82
$0.084.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -136.78M | -131.48M | -127.50M | -111.30M | -104.41M |
| Total Depreciation and Amortization | 3.11M | 3.53M | 4.11M | 4.68M | 4.94M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.50M | 8.03M | 7.52M | 5.85M | 5.96M |
| Change in Net Operating Assets | -1.02M | 779.00K | 5.05M | -6.40M | 22.28M |
| Cash from Operations | -126.18M | -119.14M | -110.82M | -107.18M | -71.24M |
| Capital Expenditure | -5.07M | -4.65M | -3.83M | -3.41M | -3.46M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.98M | -70.59M | -48.79M | -74.59M | -53.60M |
| Cash from Investing | 6.91M | -75.25M | -52.61M | -77.99M | -57.05M |
| Total Debt Issued | 32.46M | 32.46M | 32.46M | -- | -- |
| Total Debt Repaid | -17.14M | -17.14M | -17.14M | -- | -- |
| Issuance of Common Stock | 1.80M | 34.92M | 35.18M | 34.82M | 33.59M |
| Repurchase of Common Stock | -- | -- | -- | -- | -176.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 29.40M | 157.75M | 158.27M | 128.27M | 128.20M |
| Cash from Financing | 46.51M | 207.98M | 208.77M | 163.09M | 161.61M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.77M | 13.60M | 45.33M | -22.08M | 33.32M |